Cortagen – Kodiac biolabs

Our opinion on this compoundSingle-lab provenance

39/100

Intriguing transcriptional mechanism claim buried under single-lab, non-replicated evidence from one consortium

Cortagen sits in an unusual corner of the research landscape. It’s a synthetic tetrapeptide (Ala-Glu-Asp-Pro) from Vladimir Khavinson’s program at the St. Petersburg Institute of Bioregulation and Gerontology, developed as the active fragment of cortexin, a porcine cerebral cortex extract that’s been used clinically in the Russian Federation for decades. The class idea is genuinely interesting: short peptides acting as tissue-specific transcriptional modulators, binding directly to promoter GC-rich regions and modulating gene expression in cell-type-restricted ways. That’s not a trivial claim. If it holds up, it represents a compelling mechanism for precision tissue signaling without conventional receptor-dependent pharmacology.

The problem is “if it holds up.” The Khavinson program has generated a significant body of work internally, but the overwhelming majority originates from one consortium, appears in Russian-language journals, and has not been subjected to the kind of independent multi-lab replication that would give Western investigators real confidence. We think the DNA-binding mechanism story is the most interesting part of this compound, and also the part that most needs outside scrutiny. Short peptides binding specifically to gene promoters is a substantial mechanistic claim, and the biochemistry hasn’t been worked through in laboratories that dont have a stake in validating it.

For Cortagen specifically, the clinical evidence covers vegetative-vascular dystonia, post-traumatic asthenia, and discirculatory encephalopathy. These are real diagnostic categories in the Russian neurological literature, and the reported effects include cognitive recovery and neuroprotective outcomes after hypoxic or traumatic insults. But the studies are small, the methodology is largely opaque to outside reviewers, and the reported dose regimens (5-10 mg IM over 5-10 day courses) haven’t been formally characterized for PK/PD in any framework that maps cleanly to Western preclinical practice.

Within the Khavinson class itself, Cortagen isnt clearly superior to Pinealon or the other CNS-targeted fragments. The class shares a mechanism and differentiation within it is mostly tissue-targeting hypothesis rather than demonstrated superiority. Epitalon gets more Western attention because the telomere angle has a legible hook; Cortagen’s “cerebral cortex bioregulator” framing is harder to operationalize into a specific research question a Western lab could pursue without adopting the entire Khavinson framework wholesale.

Honestly, we don’t think Cortagen is junk. The transcriptional regulation angle is worth watching, and if any Western group ran the DNA-binding assays with proper controls and independent ChIP-seq or transcriptomics, that alone would be worth a paper. But right now the evidence base is too thin, too concentrated in one group, and too methodologically opaque to justify serious bench time ahead of better-evidenced alternatives in neuroprotection or cognitive biology. It scores where it does because the idea is real but the proof isnt there yet.

Novelty: 48
Mechanism promise: 52
In-category differentiation: 38
Evidence quality: 22
Translational signal: 28
Research bench value: 35

Rationale Cortagen earns modest novelty and mechanism scores for the Khavinson short-peptide DNA-binding story, but like Epitalon, the evidence base is dominated by a single originating group, lacks independent replication, and the clinical data is methodologically opaque by Western standards; differentiation within the class itself is weak.

Khavinson tetrapeptide bioregulator (Ala-Glu-Asp-Pro)

A four-residue synthetic peptide developed by the Khavinson group as a cerebral cortex bioregulator, part of the Russian short-peptide bioregulator class.

Abstract

Cortagen (Ala-Glu-Asp-Pro; CAS 254749-42-7; molecular weight 414.41) is a four-residue synthetic peptide developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson as a representative of the short-peptide bioregulator class derived from cortexin (a porcine cerebral cortex extract registered as a medicine in the Russian Federation). The Khavinson program isolated active fragments from organ-specific peptide extracts and characterized synthetic tetrapeptide and tripeptide analogs as the molecular basis of the parent extract’s activity, including Cortagen for cerebral cortex, Pinealon (Glu-Asp-Arg) for pineal/CNS, Epitalon (Ala-Glu-Asp-Gly) for pineal, Vilon (Lys-Glu) for thymus, and several others. The proposed mechanism is direct DNA binding of the short peptides at promoter regions of tissue-specific genes, modulating transcription in a cell-type-restricted manner; published Russian-language work characterizes binding to specific GC-rich regulatory regions and effects on transcription factor recruitment. Pro-cognitive and neuroprotective activities of Cortagen are reported in rodent models of cerebral hypoxia, traumatic brain injury, and stress; Russian clinical reports describe efficacy in vegetative-vascular dystonia, post-traumatic asthenia, and discirculatory encephalopathy at intramuscular doses of 5 to 10 mg over 5 to 10 day courses. The Khavinson bioregulator class is registered as medicines in the Russian Federation and a small number of CIS jurisdictions; FDA, EMA, and most Western regulatory authorities have not reviewed the class. The principal limitation on the evidence base is the dominance of the originating laboratory’s publications and the limited scale of clinical evidence relative to what would be required for Western regulatory approval. Investigators should weight the evidence accordingly.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1331Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.